Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RESEARCH TOOLSreports
Holding RNAZ?
Track your performance easily
RNAZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.22 - $18.64
Previous Close$0.34
Volume264.38K
Average Volume (3M)1.70M
Market Cap
$5.87M
Enterprise Value$2.69M
Total Cash (Recent Filing)$3.40M
Total Debt (Recent Filing)$227.25K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.05
Shares Outstanding17,265,658
10 Day Avg. Volume467,552
30 Day Avg. Volume1,696,806
Standard Deviation0.48
R-Squared0.00440
Alpha-0.10
Financial Highlights & Ratios
Price to Book (P/B)4.25
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$3.00Price Target Upside783.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
TransCode Therapeutics News
PremiumCompany Announcements
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges
Bulls Say, Bears Say
Bulls Say
Clinical Study ProgressThe Safety Review Committee monitoring the company's Phase 1 study has unanimously approved advancing to the second cohort based on favorable safety in the first cohort.
Financial Support And RecognitionAn NIH grant of $2M was awarded to the company to assist in funding the trial, demonstrating that the NIH viewed TransCode's novel RNA technology as innovative and potentially differentiating for the treatment of metastatic cancer.
Innovative Treatment TechnologyTTX-MC138 has shown potential for unique properties in treatment of solid tumors, delivering drugs directly to metastatic lesions while sparing normal tissues.
Bears Say
Clinical Program EfficacyEfficacy from clinical programs being lower than expected could hinder the company's ability to meet investor expectations and secure future funding.
Clinical Program RisksSafety signals emerging with any of the company’s clinical or preclinical programs could lead to increased scrutiny and potential setbacks.
Financial PerformanceThe company is facing a de-listing risk if shares go under $1, which could significantly impact investor confidence.
---
Ownership Overview
0.73%
Insiders
0.22% Mutual Funds
0.76% Other Institutional Investors
98.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $0.22 and its highest was $18.64 in the past 12 months.
What is TransCode Therapeutics’s market cap?
Currently, no data Available
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is in 127 days.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Nov 11, 2024. The company reported -$0.158 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.002.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 17,265,657 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$0.158 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
TransCode Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (783.13% Upside)
$3.00 (783.13% Upside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.05%
12-Months-Change
Fundamentals
Return on Equity
-1048.70%
Trailing 12-Months
Asset Growth
-61.52%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
---
RNAZ Stock 12 Month Forecast
Average Price Target
$3.00
▲(783.13% Upside)
Technical Analysis
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-62.14%
reiterated a buy rating 7 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -62.14% per trade.
---